The global market for Tumor Immunity PD-1 Inhibitors was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The development of tumor immunity PD-1 inhibitors is mainly affected by the following driving factors:

Market demand: As the number of cancer patients continues to increase around the world, the demand for innovative drugs in the cancer treatment market is also growing. As a new type of immunotherapy drug, PD-1 inhibitors have huge market potential.

Scientific and technological innovation: The development of immunotherapy provides technical support for the research and development of PD-1 inhibitors. With a deeper understanding of tumor immune mechanisms, scientists continue to explore how to use the PD-1 signaling pathway to regulate immune responses and develop more effective PD-1 inhibitors.

Policy support: Government support and encouragement policies for the pharmaceutical industry provide a good environment for the development and marketing of PD-1 inhibitors. For example, agencies such as the U.S. Food and Drug Administration (FDA) have provided a fast track for the approval of innovative drugs, accelerating the launch of PD-1 inhibitors.

Capital investment: The research and development of PD-1 inhibitors requires a large amount of financial support, including clinical trials, production and marketing. Large pharmaceutical companies and venture capital institutions are increasingly investing in the field of PD-1 inhibitors, providing financial guarantee for the development of this field.

Clinical needs: Traditional chemotherapy, radiotherapy and other treatment methods have serious side effects on cancer patients, and there are drug resistance problems. As a new type of immunotherapy drug, PD-1 inhibitors have low toxicity and good tolerability, which can meet clinical needs and improve patients" survival rate and quality of life.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Tumor Immunity PD-1 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity PD-1 Inhibitors.

The Tumor Immunity PD-1 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Immunity PD-1 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Tumor Immunity PD-1 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Tumor Immunity PD-1 Inhibitors Market Report

Report Metric	Details
Report Name	Tumor Immunity PD-1 Inhibitors Market
Segment by Type	Toripalimab Camrelizumab Atezolizumab Tislelizumab Nivolumab Others
Segment by Application	Melanoma Treatment Non-Small Cell Lung Cancer Treatment Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck, Novartis, Sumitomo Dainippon Pharma, Genentech (Roche), AstraZeneca, Pfizer, GSK, Regeneron Pharmaceuticals, Eli Lilly, Jiangsu Hengrui Pharmaceuticals, Curis Inc., Bristol-Myers Squibb, Junshi Biosciences, Innovent Biologics, BeiGene
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tumor Immunity PD-1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tumor Immunity PD-1 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Tumor Immunity PD-1 Inhibitors Market report?

Ans: The main players in the Tumor Immunity PD-1 Inhibitors Market are Merck, Novartis, Sumitomo Dainippon Pharma, Genentech (Roche), AstraZeneca, Pfizer, GSK, Regeneron Pharmaceuticals, Eli Lilly, Jiangsu Hengrui Pharmaceuticals, Curis Inc., Bristol-Myers Squibb, Junshi Biosciences, Innovent Biologics, BeiGene

What are the Application segmentation covered in the Tumor Immunity PD-1 Inhibitors Market report?

Ans: The Applications covered in the Tumor Immunity PD-1 Inhibitors Market report are Melanoma Treatment, Non-Small Cell Lung Cancer Treatment, Others

What are the Type segmentation covered in the Tumor Immunity PD-1 Inhibitors Market report?

Ans: The Types covered in the Tumor Immunity PD-1 Inhibitors Market report are Toripalimab, Camrelizumab, Atezolizumab, Tislelizumab, Nivolumab, Others

1 Tumor Immunity PD-1 Inhibitors Market Overview

1.1 Product Definition

1.2 Tumor Immunity PD-1 Inhibitors by Type

1.2.1 Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Type (2024 VS 2031)

1.2.2 Toripalimab

1.2.3 Camrelizumab

1.2.4 Atezolizumab

1.2.5 Tislelizumab

1.2.6 Nivolumab

1.2.7 Others

1.3 Tumor Immunity PD-1 Inhibitors by Application

1.3.1 Global Tumor Immunity PD-1 Inhibitors Market Value by Application (2024 VS 2031)

1.3.2 Melanoma Treatment

1.3.3 Non-Small Cell Lung Cancer Treatment

1.3.4 Others

1.4 Global Tumor Immunity PD-1 Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Tumor Immunity PD-1 Inhibitors Revenue 2020-2031

1.4.2 Global Tumor Immunity PD-1 Inhibitors Sales 2020-2031

1.4.3 Global Tumor Immunity PD-1 Inhibitors Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Tumor Immunity PD-1 Inhibitors Market Competition by Manufacturers

2.1 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Manufacturers (2020-2025)

2.2 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Tumor Immunity PD-1 Inhibitors Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Tumor Immunity PD-1 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Product Type & Application

2.7 Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Date of Enter into This Industry

2.8 Global Tumor Immunity PD-1 Inhibitors Market Competitive Situation and Trends

2.8.1 Global Tumor Immunity PD-1 Inhibitors Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Tumor Immunity PD-1 Inhibitors Players Market Share by Revenue

2.8.3 Global Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Tumor Immunity PD-1 Inhibitors Market Scenario by Region

3.1 Global Tumor Immunity PD-1 Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Tumor Immunity PD-1 Inhibitors Sales by Region: 2020-2031

3.2.1 Global Tumor Immunity PD-1 Inhibitors Sales by Region: 2020-2025

3.2.2 Global Tumor Immunity PD-1 Inhibitors Sales by Region: 2026-2031

3.3 Global Tumor Immunity PD-1 Inhibitors Revenue by Region: 2020-2031

3.3.1 Global Tumor Immunity PD-1 Inhibitors Revenue by Region: 2020-2025

3.3.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Region: 2026-2031

3.4 North America Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country

3.4.1 North America Tumor Immunity PD-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2031)

3.4.3 North America Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country

3.5.1 Europe Tumor Immunity PD-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2031)

3.5.3 Europe Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2031)

3.6.3 Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country

3.7.1 Latin America Tumor Immunity PD-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2031)

3.7.3 Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2031)

3.8.3 Middle East and Africa Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Tumor Immunity PD-1 Inhibitors Sales by Type (2020-2031)

4.1.1 Global Tumor Immunity PD-1 Inhibitors Sales by Type (2020-2025)

4.1.2 Global Tumor Immunity PD-1 Inhibitors Sales by Type (2026-2031)

4.1.3 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2020-2031)

4.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Type (2020-2031)

4.2.1 Global Tumor Immunity PD-1 Inhibitors Revenue by Type (2020-2025)

4.2.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Type (2026-2031)

4.2.3 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Type (2020-2031)

4.3 Global Tumor Immunity PD-1 Inhibitors Price by Type (2020-2031)

5 Segment by Application

5.1 Global Tumor Immunity PD-1 Inhibitors Sales by Application (2020-2031)

5.1.1 Global Tumor Immunity PD-1 Inhibitors Sales by Application (2020-2025)

5.1.2 Global Tumor Immunity PD-1 Inhibitors Sales by Application (2026-2031)

5.1.3 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2020-2031)

5.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Application (2020-2031)

5.2.1 Global Tumor Immunity PD-1 Inhibitors Revenue by Application (2020-2025)

5.2.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Application (2026-2031)

5.2.3 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Application (2020-2031)

5.3 Global Tumor Immunity PD-1 Inhibitors Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merck

6.1.1 Merck Company Information

6.1.2 Merck Description and Business Overview

6.1.3 Merck Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merck Tumor Immunity PD-1 Inhibitors Product Portfolio

6.1.5 Merck Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Novartis Tumor Immunity PD-1 Inhibitors Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Sumitomo Dainippon Pharma

6.3.1 Sumitomo Dainippon Pharma Company Information

6.3.2 Sumitomo Dainippon Pharma Description and Business Overview

6.3.3 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Portfolio

6.3.5 Sumitomo Dainippon Pharma Recent Developments/Updates

6.4 Genentech (Roche)

6.4.1 Genentech (Roche) Company Information

6.4.2 Genentech (Roche) Description and Business Overview

6.4.3 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Portfolio

6.4.5 Genentech (Roche) Recent Developments/Updates

6.5 AstraZeneca

6.5.1 AstraZeneca Company Information

6.5.2 AstraZeneca Description and Business Overview

6.5.3 AstraZeneca Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.5.4 AstraZeneca Tumor Immunity PD-1 Inhibitors Product Portfolio

6.5.5 AstraZeneca Recent Developments/Updates

6.6 Pfizer

6.6.1 Pfizer Company Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Pfizer Tumor Immunity PD-1 Inhibitors Product Portfolio

6.6.5 Pfizer Recent Developments/Updates

6.7 GSK

6.7.1 GSK Company Information

6.7.2 GSK Description and Business Overview

6.7.3 GSK Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.7.4 GSK Tumor Immunity PD-1 Inhibitors Product Portfolio

6.7.5 GSK Recent Developments/Updates

6.8 Regeneron Pharmaceuticals

6.8.1 Regeneron Pharmaceuticals Company Information

6.8.2 Regeneron Pharmaceuticals Description and Business Overview

6.8.3 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Portfolio

6.8.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.9 Eli Lilly

6.9.1 Eli Lilly Company Information

6.9.2 Eli Lilly Description and Business Overview

6.9.3 Eli Lilly Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Eli Lilly Tumor Immunity PD-1 Inhibitors Product Portfolio

6.9.5 Eli Lilly Recent Developments/Updates

6.10 Jiangsu Hengrui Pharmaceuticals

6.10.1 Jiangsu Hengrui Pharmaceuticals Company Information

6.10.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview

6.10.3 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Portfolio

6.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

6.11 Curis Inc.

6.11.1 Curis Inc. Company Information

6.11.2 Curis Inc. Description and Business Overview

6.11.3 Curis Inc. Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Curis Inc. Tumor Immunity PD-1 Inhibitors Product Portfolio

6.11.5 Curis Inc. Recent Developments/Updates

6.12 Bristol-Myers Squibb

6.12.1 Bristol-Myers Squibb Company Information

6.12.2 Bristol-Myers Squibb Description and Business Overview

6.12.3 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Portfolio

6.12.5 Bristol-Myers Squibb Recent Developments/Updates

6.13 Junshi Biosciences

6.13.1 Junshi Biosciences Company Information

6.13.2 Junshi Biosciences Description and Business Overview

6.13.3 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Portfolio

6.13.5 Junshi Biosciences Recent Developments/Updates

6.14 Innovent Biologics

6.14.1 Innovent Biologics Company Information

6.14.2 Innovent Biologics Description and Business Overview

6.14.3 Innovent Biologics Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Portfolio

6.14.5 Innovent Biologics Recent Developments/Updates

6.15 BeiGene

6.15.1 BeiGene Company Information

6.15.2 BeiGene Description and Business Overview

6.15.3 BeiGene Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.15.4 BeiGene Tumor Immunity PD-1 Inhibitors Product Portfolio

6.15.5 BeiGene Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Tumor Immunity PD-1 Inhibitors Industry Chain Analysis

7.2 Tumor Immunity PD-1 Inhibitors Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Tumor Immunity PD-1 Inhibitors Production Mode & Process Analysis

7.4 Tumor Immunity PD-1 Inhibitors Sales and Marketing

7.4.1 Tumor Immunity PD-1 Inhibitors Sales Channels

7.4.2 Tumor Immunity PD-1 Inhibitors Distributors

7.5 Tumor Immunity PD-1 Inhibitors Customer Analysis

8 Tumor Immunity PD-1 Inhibitors Market Dynamics

8.1 Tumor Immunity PD-1 Inhibitors Industry Trends

8.2 Tumor Immunity PD-1 Inhibitors Market Drivers

8.3 Tumor Immunity PD-1 Inhibitors Market Challenges

8.4 Tumor Immunity PD-1 Inhibitors Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Merck

Novartis

Sumitomo Dainippon Pharma

Regeneron Pharmaceuticals

Eli Lilly

Jiangsu Hengrui Pharmaceuticals

List of Tables

Table 1. Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Tumor Immunity PD-1 Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Tumor Immunity PD-1 Inhibitors Market Competitive Situation by Manufacturers in 2024

Table 4. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Tumor Immunity PD-1 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Tumor Immunity PD-1 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Tumor Immunity PD-1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity PD-1 Inhibitors as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K Units)

Table 18. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2020-2025)

Table 19. Global Tumor Immunity PD-1 Inhibitors Sales by Region (2026-2031) & (K Units)

Table 20. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2026-2031)

Table 21. Global Tumor Immunity PD-1 Inhibitors Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2020-2025)

Table 23. Global Tumor Immunity PD-1 Inhibitors Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2026-2031)

Table 25. North America Tumor Immunity PD-1 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K Units)

Table 27. North America Tumor Immunity PD-1 Inhibitors Sales by Country (2026-2031) & (K Units)

Table 28. North America Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Tumor Immunity PD-1 Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Tumor Immunity PD-1 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K Units)

Table 32. Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2026-2031) & (K Units)

Table 33. Europe Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Tumor Immunity PD-1 Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Tumor Immunity PD-1 Inhibitors Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Tumor Immunity PD-1 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Tumor Immunity PD-1 Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Tumor Immunity PD-1 Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Type (2020-2025)

Table 51. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Type (2026-2031)

Table 52. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2020-2025)

Table 53. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2026-2031)

Table 54. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Type (2020-2025)

Table 57. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Type (2026-2031)

Table 58. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Type (2020-2025)

Table 59. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Type (2026-2031)

Table 60. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Application (2020-2025)

Table 61. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Application (2026-2031)

Table 62. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2020-2025)

Table 63. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2026-2031)

Table 64. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Application (2020-2025)

Table 67. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Application (2026-2031)

Table 68. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Application (2020-2025)

Table 69. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Application (2026-2031)

Table 70. Merck Company Information

Table 71. Merck Description and Business Overview

Table 72. Merck Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Merck Tumor Immunity PD-1 Inhibitors Product

Table 74. Merck Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Novartis Tumor Immunity PD-1 Inhibitors Product

Table 79. Novartis Recent Developments/Updates

Table 80. Sumitomo Dainippon Pharma Company Information

Table 81. Sumitomo Dainippon Pharma Description and Business Overview

Table 82. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product

Table 84. Sumitomo Dainippon Pharma Recent Developments/Updates

Table 85. Genentech (Roche) Company Information

Table 86. Genentech (Roche) Description and Business Overview

Table 87. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product

Table 89. Genentech (Roche) Recent Developments/Updates

Table 90. AstraZeneca Company Information

Table 91. AstraZeneca Description and Business Overview

Table 92. AstraZeneca Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. AstraZeneca Tumor Immunity PD-1 Inhibitors Product

Table 94. AstraZeneca Recent Developments/Updates

Table 95. Pfizer Company Information

Table 96. Pfizer Description and Business Overview

Table 97. Pfizer Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Pfizer Tumor Immunity PD-1 Inhibitors Product

Table 99. Pfizer Recent Developments/Updates

Table 100. GSK Company Information

Table 101. GSK Description and Business Overview

Table 102. GSK Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. GSK Tumor Immunity PD-1 Inhibitors Product

Table 104. GSK Recent Developments/Updates

Table 105. Regeneron Pharmaceuticals Company Information

Table 106. Regeneron Pharmaceuticals Description and Business Overview

Table 107. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product

Table 109. Regeneron Pharmaceuticals Recent Developments/Updates

Table 110. Eli Lilly Company Information

Table 111. Eli Lilly Description and Business Overview

Table 112. Eli Lilly Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Eli Lilly Tumor Immunity PD-1 Inhibitors Product

Table 114. Eli Lilly Recent Developments/Updates

Table 115. Jiangsu Hengrui Pharmaceuticals Company Information

Table 116. Jiangsu Hengrui Pharmaceuticals Description and Business Overview

Table 117. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product

Table 119. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

Table 120. Curis Inc. Company Information

Table 121. Curis Inc. Description and Business Overview

Table 122. Curis Inc. Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Curis Inc. Tumor Immunity PD-1 Inhibitors Product

Table 124. Curis Inc. Recent Developments/Updates

Table 125. Bristol-Myers Squibb Company Information

Table 126. Bristol-Myers Squibb Description and Business Overview

Table 127. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product

Table 129. Bristol-Myers Squibb Recent Developments/Updates

Table 130. Junshi Biosciences Company Information

Table 131. Junshi Biosciences Description and Business Overview

Table 132. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product

Table 134. Junshi Biosciences Recent Developments/Updates

Table 135. Innovent Biologics Company Information

Table 136. Innovent Biologics Description and Business Overview

Table 137. Innovent Biologics Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 138. Innovent Biologics Tumor Immunity PD-1 Inhibitors Product

Table 139. Innovent Biologics Recent Developments/Updates

Table 140. BeiGene Company Information

Table 141. BeiGene Description and Business Overview

Table 142. BeiGene Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 143. BeiGene Tumor Immunity PD-1 Inhibitors Product

Table 144. BeiGene Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Tumor Immunity PD-1 Inhibitors Distributors List

Table 148. Tumor Immunity PD-1 Inhibitors Customers List

Table 149. Tumor Immunity PD-1 Inhibitors Market Trends

Table 150. Tumor Immunity PD-1 Inhibitors Market Drivers

Table 151. Tumor Immunity PD-1 Inhibitors Market Challenges

Table 152. Tumor Immunity PD-1 Inhibitors Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

Table 156. Authors List of This Report

List of Figures

Figure 1. Product Picture of Tumor Immunity PD-1 Inhibitors

Figure 2. Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Tumor Immunity PD-1 Inhibitors Market Share by Type: 2024 & 2031

Figure 4. Toripalimab Product Picture

Figure 5. Camrelizumab Product Picture

Figure 6. Atezolizumab Product Picture

Figure 7. Tislelizumab Product Picture

Figure 8. Nivolumab Product Picture

Figure 9. Others Product Picture

Figure 10. Global Tumor Immunity PD-1 Inhibitors Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Tumor Immunity PD-1 Inhibitors Market Share by Application: 2024 & 2031

Figure 12. Melanoma Treatment

Figure 13. Non-Small Cell Lung Cancer Treatment

Figure 14. Others

Figure 15. Global Tumor Immunity PD-1 Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Tumor Immunity PD-1 Inhibitors Market Size (2020-2031) & (US$ Million)

Figure 17. Global Tumor Immunity PD-1 Inhibitors Sales (2020-2031) & (K Units)

Figure 18. Global Tumor Immunity PD-1 Inhibitors Average Price (US$/Unit) & (2020-2031)

Figure 19. Tumor Immunity PD-1 Inhibitors Report Years Considered

Figure 20. Tumor Immunity PD-1 Inhibitors Sales Share by Manufacturers in 2024

Figure 21. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers in 2024

Figure 22. Global 5 and 10 Largest Tumor Immunity PD-1 Inhibitors Players: Market Share by Revenue in Tumor Immunity PD-1 Inhibitors in 2024

Figure 23. Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 24. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 25. North America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2020-2031)

Figure 26. North America Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2020-2031)

Figure 27. United States Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Canada Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Europe Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2020-2031)

Figure 30. Europe Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2020-2031)

Figure 31. Germany Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. France Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. U.K. Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Italy Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Russia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2020-2031)

Figure 37. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2020-2031)

Figure 38. China Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Japan Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. South Korea Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. India Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Australia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. China Taiwan Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Southeast Asia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2020-2031)

Figure 46. Latin America Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. UAE Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Tumor Immunity PD-1 Inhibitors by Type (2020-2031)

Figure 56. Global Revenue Market Share of Tumor Immunity PD-1 Inhibitors by Type (2020-2031)

Figure 57. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Type (2020-2031)

Figure 58. Global Sales Market Share of Tumor Immunity PD-1 Inhibitors by Application (2020-2031)

Figure 59. Global Revenue Market Share of Tumor Immunity PD-1 Inhibitors by Application (2020-2031)

Figure 60. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Application (2020-2031)

Figure 61. Tumor Immunity PD-1 Inhibitors Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions